GlassScriptPhysician profile
Benjamin A Jeffrey
NPI 1699197426
$1,276.00
in general payments reported to CMS, 2019-2025
19 companies · $513 in 2025
The $513 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.34 · 2022: $296 · 2023: $236 · 2024: $182 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $314.87 | 2022-2025 | |
| Axsome Therapeutics, INC. | $173.63 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $106.12 | 2022-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.42 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $85.93 | 2022-2025 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $73.79 | 2025 | Uzedy |
| Supernus Pharmaceuticals, INC. | $61.02 | 2022-2024 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $50.12 | 2023 | Abilify Mycite, Rexulti |
| Lundbeck LLC | $49.34 | 2021 | |
| Alkermes, INC. | $43.68 | 2022-2023 | Lybalvi |
| Idorsia Pharmaceuticals US INC | $40.43 | 2023-2024 | Quviviq |
| Tms Neurohealth Centers INC. | $38.13 | 2025 | Tms Neurohealth Centers INC. |
| Merck Sharp & Dohme LLC | $30.97 | 2022-2023 | Belsomra |
| Neurocrine Biosciences, INC. | $22.07 | 2023 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $18.11 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $17.34 | 2023 | Jornay Pm |
| Tris Pharma INC | $17.27 | 2024 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $14.92 | 2022 | |
| Neos Therapeutics, LP | $13.84 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Jeffrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.